Monday, December 7, 2015
Almac Group, a Craigavon, Northern Ireland-based global contract development and manufacturing organization, has confirmed a £16 million ($24.3 million) investment to expand its formulation and analytical development services to meet ongoing client demand.
A new 23 million euro ($25 million) initiative to accelerate the search for an effective HIV vaccine have been launched.
The Dementia Discovery Fund, a new initiative designed to speed up the discovery and development of new treatments for dementia, has launched after securing $100 million backing from worldwide investors. The U.K. government’s Department of Health, Alzheimer’s Research U.K. and pharmaceutical companies including Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda have joined forces to support the innovative new fund.
San Francisco-based goBalto, a provider of cloud-based clinical study startup solutions, has announced compliance with new European regulatory directives aimed at creating an environment that is favorable for conducting clinical trials across the European Union.
Peregrine Pharmaceuticals, a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a second, later-stage trial.
Cancer Research U.K.-funded scientists have developed a blood test that could help pair cancer patients with the most suitable therapy for their disease and then track the tumor’s progress to see if the treatment is working, according to research published in Clinical Cancer Research.
Western Europe boasts one of the largest and most active markets for clinical trials. Indeed, more than one in five active clinical investigators is based in Western Europe, and the growth in sponsor spending there now outpaces that in the U.S.
Recipharm, a contract development and manufacturing organization, plans to cut 100 positions in the Greater Stockholm area of Sweden.
Crown Bioscience, a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research, has tripled the size of its team in Europe to meet demand for its services.